Who are LY2062430's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ODM-203 (Period 1), E3810, DMB-3115.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ly2062430.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LY2062430 — Competitive Intelligence Brief

LY2062430 (LY2062430) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE10A inhibitor. Area: Neurology/Psychiatry.

phase 3 PDE10A inhibitor PDE10A (Phosphodiesterase 10A) Neurology/Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

LY2062430 (LY2062430) — Eli Lilly and Company. LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LY2062430 TARGET	LY2062430	Eli Lilly and Company	phase 3	PDE10A inhibitor	PDE10A (Phosphodiesterase 10A)
ODM-203 (Period 1)	ODM-203 (Period 1)	Orion Corporation, Orion Pharma	marketed	PDE10A inhibitor	PDE10A (phosphodiesterase 10A)
E3810	E3810	Eisai Co., Ltd.	phase 3	PDE10A inhibitor	PDE10A (Phosphodiesterase 10A)
DMB-3115	DMB-3115	Dong-A ST Co., Ltd.	phase 3	PDE10A inhibitor	PDE10A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE10A inhibitor class)

Dong-A ST Co., Ltd. · 1 drug in this class
Eisai Co., Ltd. · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LY2062430 — Competitive Intelligence Brief. https://druglandscape.com/ci/ly2062430. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab